Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced annual results with net profit attributable to parent of 290 million yuan, a decrease of 38.32% year-on-year.

Shandong Xinhua Pharmaceutical Co., Ltd. (00719) has released its annual results for the year ended December 31, 2025. Revenue was 8.755 billion yuan (RMB, the same below), up 3.41% year over year; net profit attributable to shareholders was 290 million yuan, down 38.32% year over year; basic earnings per share were 0.42 yuan. It plans to pay a final dividend of 0.15 yuan per share.

According to the announcement, the company obtained 47 drug approvals throughout the year, setting a historic high. The pace of major innovative drug R&D has accelerated. Enrollment of subjects for the Phase II clinical trial of OAB-14 for the treatment of Alzheimer’s disease is nearly complete; preparation for the Phase III clinical study of LXH-2301 for the treatment of gout has been initiated; LXH-1211 for pulmonary arterial hypertension obtained a Phase I clinical approval; and the innovative drug LXH-2103 for the treatment of moderate-to-severe pain has completed the Pre-IND filing. During the year, it obtained 48 authorized patents. One project won the Second Prize for Scientific and Technological Progress in Shandong Province; one project won the First Prize in Shandong Province’s Science and Technology Workers’ Innovation Competition; one project was included in the provincial key R&D plan; and two projects entered the provincial major innovation task guideline.

The company is accelerating the upgrade and replacement of formulation products. In March 2025, it was selected for the 11th national centralized procurement round for 3 products; 31 products were awarded in alliance-based procurement as part of the national centralized procurement succession volume. It has formed a new generation of key formulation product cluster, represented by enteric-coated sustained-release aspirin tablets, sevelamer carbonate tablets, and others. Leveraging its comprehensive advantage in raw material drugs, domestic sales revenue maintained stable growth, and the domestic market shares of key products such as ibuprofen and cabapetrin calcium further expanded. Leveraging product technology advantages, export volumes of the starch-granule series such as metamizole and aspirin and ibuprofen achieved substantial progress. The export volumes year over year for specialty raw material drugs meloxicam, glimepiride, and sevelamer carbonate increased significantly. The role in ensuring the supply and the capability for development of pharmaceutical intermediates has been strengthened.

A massive amount of news and precise analysis—exclusively on the Sina Finance APP